ALME Stock Overview
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 1/6 |
Almirall, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €8.54 |
52 Week High | €9.31 |
52 Week Low | €7.87 |
Beta | 0.36 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -23.78% |
5 Year Change | -43.22% |
Change since IPO | 26.33% |
Recent News & Updates
Recent updates
Shareholder Returns
ALME | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0% | 0.2% | -1.4% |
1Y | n/a | -5.3% | -2.4% |
Return vs Industry: Insufficient data to determine how ALME performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ALME performed against the UK Market.
Price Volatility
ALME volatility | |
---|---|
ALME Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 8.7% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ALME has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALME's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1943 | 1,876 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Wynzora, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel.
Almirall, S.A. Fundamentals Summary
ALME fundamental statistics | |
---|---|
Market cap | €1.83b |
Earnings (TTM) | €6.98m |
Revenue (TTM) | €907.01m |
262.5x
P/E Ratio2.0x
P/S RatioIs ALME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALME income statement (TTM) | |
---|---|
Revenue | €907.01m |
Cost of Revenue | €227.28m |
Gross Profit | €679.73m |
Other Expenses | €672.75m |
Earnings | €6.98m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 19, 2024
Earnings per share (EPS) | 0.033 |
Gross Margin | 74.94% |
Net Profit Margin | 0.77% |
Debt/Equity Ratio | 23.2% |
How did ALME perform over the long term?
See historical performance and comparison